Heilongjiang ZBD Pharmaceutical Co., Ltd.

XSSC:603567 Stock Report

Market Cap: CN¥10.9b

Heilongjiang ZBD Pharmaceutical Past Earnings Performance

Past criteria checks 5/6

Heilongjiang ZBD Pharmaceutical has been growing earnings at an average annual rate of 3.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 0.8% per year. Heilongjiang ZBD Pharmaceutical's return on equity is 7.8%, and it has net margins of 21%.

Key information

3.9%

Earnings growth rate

0.8%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate0.8%
Return on equity7.8%
Net Margin21.0%
Next Earnings Update26 Apr 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Heilongjiang ZBD Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSSC:603567 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,11765362149
30 Jun 243,24876378967
31 Mar 242,72351286870
31 Dec 233,13847398380
30 Sep 232,9462491,11775
30 Jun 233,286491,01069
31 Mar 234,7432821,03074
31 Dec 224,21418588571
30 Sep 224,74024379661
30 Jun 224,97529588457
31 Mar 224,4043351,00755
31 Dec 214,12733299755
30 Sep 214,3324381,10870
30 Jun 213,6715281,06971
31 Mar 213,5094651,06484
31 Dec 203,4044361,08981
30 Sep 202,9563121,14267
30 Jun 203,1863561,16675
31 Mar 203,1253661,07786
31 Dec 193,2924091,19787
30 Sep 192,9154281,15692
30 Jun 192,9874511,19992
31 Mar 192,9604741,32975
01 Jan 192,7814621,24891
30 Sep 183,1905391,311103
30 Jun 183,2355701,187140
31 Mar 183,1995611,072118
31 Dec 173,13752198494
30 Sep 172,8584851,07557
30 Jun 172,6295011,1330
31 Mar 172,5295601,0380
31 Dec 162,3915109940
30 Sep 162,2626707960
30 Jun 162,2575548970
31 Mar 162,2746258800
31 Dec 152,0735858420
30 Sep 151,9285016970
30 Jun 151,5984964720
31 Mar 151,6594954080
31 Dec 141,5934773830

Quality Earnings: 603567 has high quality earnings.

Growing Profit Margin: 603567's current net profit margins (21%) are higher than last year (8.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 603567's earnings have grown by 3.9% per year over the past 5 years.

Accelerating Growth: 603567's earnings growth over the past year (162.4%) exceeds its 5-year average (3.9% per year).

Earnings vs Industry: 603567 earnings growth over the past year (162.4%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 603567's Return on Equity (7.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 09:11
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Heilongjiang ZBD Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wen Wen ShenAvic Securities Co., Ltd
Song YangTianfeng Securities Brokerage Co., Ltd